Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Saxagliptin
Drug ID BADD_D01992
Description Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status Prescription
ATC Code A10BH03
DrugBank ID DB06335
KEGG ID D08996
MeSH ID C502994
PubChem ID 11235729
TTD Drug ID D0K9MY
NDC Product Code 0310-6105; 55154-6931; 11722-078; 0310-6100; 50370-0030; 50193-4212
Synonyms saxagliptin | 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate | Onglyza | BMS 477118 | BMS477118 | BMS-477118
Chemical Information
Molecular Formula C18H25N3O2
CAS Registry Number 361442-04-8
SMILES C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac failureDipeptidyl peptidase 4P27487T3139125453730
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastritis07.08.02.001--
Gastroenteritis11.01.07.004; 07.19.03.0010.001500%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glomerular filtration rate decreased13.13.01.0090.002251%Not Available
Glycosylated haemoglobin increased13.02.02.0050.002251%Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.0010.001500%Not Available
Hepatocellular injury09.01.07.0080.001500%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000979%
Hyperhidrosis23.02.03.004; 08.01.03.0280.001500%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertriglyceridaemia14.08.02.001--
Hyperuricaemia14.09.01.0030.001500%
Hypocalcaemia14.04.01.0040.002251%
Hypoglycaemia14.06.03.001; 05.06.03.0010.005251%
Hypokalaemia14.05.03.0020.003001%
Hyponatraemia14.05.04.0020.001500%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.002251%Not Available
Intestinal obstruction07.13.01.0020.001500%Not Available
Lipase increased13.05.01.0030.003001%
Liver disorder09.01.08.0010.001500%Not Available
Loss of consciousness17.02.04.0040.001500%Not Available
Lymphocyte count decreased13.01.06.006--
Lymphoma01.12.01.001; 16.20.01.0010.000391%Not Available
Lymphopenia01.02.02.002--Not Available
Malaise08.01.01.003--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages